Medpace Voice

Every missed patient in a rare disease clinical trial represents more than a recruitment challenge, it represents a missed opportunity...

For many patients, the journey to a clinical trial does not begin with a diagnosis, it begins with unanswered questions....

Neurodegenerative clinical trials present unique challenges that extend beyond scientific and operational complexity. Disease progression, caregiver responsibilities, travel burden, complex...

The rheumatology landscape continues to evolve as new therapies, technologies, and strategies transform drug development. Many of these advances in...

Retina development continues to be driven by converging scientific, demographic, and commercial forces. With a rapidly growing patient population, and strong investor interest, there is a push for more assets into…

Discover key insights from the third Alport Research Hub Symposium and learn how Medpace's expertise advances rare nephrology research.

In this Q&A, Lauren Shannon discusses her experience and the role that Medpace plays in advancing innovative rare disease therapies.

Ophthalmic gene therapy clinical trials aim to correct or replace genes in the eye to slow, halt, or reverse inherited...

As innovation accelerates across diabetes and endocrinology – particularly in areas like type 1 and type 2 diabetes, cell and...

Featuring: Dr. Sonia Quintas, MD, MSc, Theresa Veira, MSN, MBA, and Pora Kuperman, MPH, PhD Migraine is a leading cause...